Central retinal vein occlusion: Difference between revisions

No edit summary
No edit summary
Line 21: Line 21:
==Management==
==Management==
*Consult ophtho and neuro  
*Consult ophtho and neuro  
*Aspirin
*Complex treatment involving lowering IOP, topical steroids, cyclocryotherapy, photocoagulation while managing underlying medical diseases
*Complex treatment involving lowering IOP, topical steroids, cyclocryotherapy, photocoagulation while managing underlying medical diseases
*Possible benefit from LMWH plus aspirin in central retinal vein occlusion<ref>Lazo-Langner A et al. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica. 2010 Sep; 95(9): 1587–1593.</ref>
**May be ~80% risk reduction of adverse ocular outcome in central
**Less benefit in branched retinal vein occlusion


== See Also ==
== See Also ==

Revision as of 07:40, 2 February 2016

Background

CRVO Blood and Thunder

Risk Factors

  • DM
  • HTN
  • Hypercoagulable states
  • Vasculitis
  • Glaucoma

Clinical Features

  • Loss of vision
    • Variable, ranging from vague blurring to rapid, painless monocular vision loss

Differential Diagnosis

Acute Vision Loss (Noninflamed)

Emergent Diagnosis

Diagnosis

  • Fundoscopy
    • Optic disc edema, dilated and tortuous veins, diffuse retinal hemorrhages ("blood-and-thunder fundus")

Management

  • Consult ophtho and neuro
  • Aspirin
  • Complex treatment involving lowering IOP, topical steroids, cyclocryotherapy, photocoagulation while managing underlying medical diseases
  • Possible benefit from LMWH plus aspirin in central retinal vein occlusion[1]
    • May be ~80% risk reduction of adverse ocular outcome in central
    • Less benefit in branched retinal vein occlusion

See Also

Acute Vision Loss (Noninflamed)

References

  1. Lazo-Langner A et al. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica. 2010 Sep; 95(9): 1587–1593.